Sara Monteverdi
Overview
Explore the profile of Sara Monteverdi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Veccia A, Dipasquale M, Lorenzi M, Monteverdi S, Kinspergher S, Zambotti E, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002263
The treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) patients was dramatically revolutionized by the introduction of EGFR tyrosine kinase inhibitors in clinical practice, both in advanced...
2.
Ferro A, Campora M, Caldara A, De Lisi D, Lorenzi M, Monteverdi S, et al.
J Clin Med
. 2024 Jun;
13(12).
PMID: 38930141
Estrogen receptor (ER)-positive breast cancer (BC) is the most common BC subtype. Endocrine therapy (ET) targeting ER signaling still remains the mainstay treatment option for hormone receptor (HR)-positive BC either...
3.
Ferro A, Generali D, Caffo O, Caldara A, De Lisi D, Dipasquale M, et al.
Semin Oncol
. 2023 Sep;
50(3-5):90-101.
PMID: 37673696
Endocrine therapy (ET) targeting estrogen receptor (ER) signaling is still the mainstay treatment option for early or advanced ER-positive breast cancer (BC) and may involve suppressing estrogen production by means...
4.
Pedersini R, Cosentini D, Rinaudo L, Zamparini M, Ulivieri F, di Mauro P, et al.
Bone Rep
. 2023 Jan;
18:101654.
PMID: 36700242
Background: Bone mineral density (BMD) lacks sensitivity in individual fracture risk assessment in early breast cancer (EBC) patients treated with aromatase inhibitors (AIs). New dual-energy X-ray absorptiometry (DXA) based risk...
5.
Veccia A, Dipasquale M, Kinspergher S, Monteverdi S, Girlando S, Barbareschi M, et al.
Target Oncol
. 2022 Dec;
18(1):129-138.
PMID: 36482151
Background: KRAS is the most frequently mutated gene in non-small cell lung cancer (NSCLC), however conflicting data are available on its role as a biomarker. Objective: The aim of our...
6.
Pedersini R, di Mauro P, Amoroso V, Castronovo V, Zamparini M, Monteverdi S, et al.
Breast
. 2022 Oct;
66:162-168.
PMID: 36288635
Introduction: Whether adjuvant therapy with aromatase inhibitors (AIs) causes sleep disturbances or not in postmenopausal women with early breast cancer (EBC) is still a controversial issue. Methods: Between March 2014...
7.
Pedersini R, di Mauro P, Zamparini M, Bosio S, Zanini B, Amoroso V, et al.
In Vivo
. 2022 Jun;
36(4):1860-1867.
PMID: 35738619
Background/aim: Chemotherapy-induced taste alterations (TAs) affect approximately 53-84% of breast cancer patients with significant consequences on flavor perception, possibly leading to food aversion and changes in daily dietary habits. The...
8.
Pedersini R, Zamparini M, Bosio S, di Mauro P, Turla A, Monteverdi S, et al.
Support Care Cancer
. 2022 May;
30(8):6955-6961.
PMID: 35538327
Purpose: Dysgeusia and taste alterations (TAs) are side effects of cytotoxic chemotherapy and affect patients' quality of life; however, the prevalence, types, and duration of TAs and their potential relationship...
9.
Monteverdi S, Vita E, Sartori G, Ferrara M, DArgento E, Tortora G, et al.
Transl Cancer Res
. 2022 Feb;
9(2):409-414.
PMID: 35117384
No abstract available.
10.
Gurizzan C, Pedersini R, Fornaro C, Sardini C, Zamparini M, Monteverdi S, et al.
Front Oncol
. 2021 Nov;
11:707346.
PMID: 34722252
Objective: To evaluate the efficacy of clinical triage of oncological patients for safe continuation of cancer therapy implemented during the first SARS-CoV-2 outbreak. Methods: Between 25 February and 21 April...